Resignation of Chief Executive Officer
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Noxopharm Ltd. has announced the resignation of its Chief Executive Officer and Managing Director, Dr. Gisela Mautner, effective immediately. The Chairman expressed gratitude for her contributions and indicated that a successor will be announced soon.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Noxopharm
- Appendix 4D and FY2026 Half Year Financial Report
- R&D rebate strengthens cash position
- At-the-Market (ATM) agreement with Acuity Capital
- Sofra breakthrough science publish in major medical journal
- December 2025 Quarterly Activities Report and Appendix 4C
Later from Noxopharm
- Noxopharm appoints Dr Olivier Laczka as new CEO
- Positive SOF-SKN dosing data shows prolonged skin retention
- March 2026 Quarterly Activities Report and Appendix 4C
- Innovative collaboration further expands Sofra platform
- New data shows SOF-SKN active ingredient efficacy
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm